Global Cancer Nanomedicine Market Growth 2022-2028
Nanomedicine is a branch of nanotechnology that uses nanoparticles to diagnose, treat, monitor, and control biological systems. By manipulating materials at the nanoscale, it improves medicine delivery. As a result, nanomedicine has helped treat a wide range of diseases. Nanomedicine is still in its infancy, with numerous products in the works. Nanobiotix has identified 230 nanomedicine products that are either patented or in the early stages of development. 49 of the 230 products are on the market, while the remaining 122 are in clinical trials, either in Phase II or Phase III trials.
The global market for Cancer Nanomedicine is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Cancer Nanomedicine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Cancer Nanomedicine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Cancer Nanomedicine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Cancer Nanomedicine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Cancer Nanomedicine players cover Alnylam Pharmaceuticals, Inc, Amgen Inc, Arrowhead Pharmaceuticals, Inc, AstraZeneca and Cadila Pharmaceuticals, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Cancer Nanomedicine market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Cancer Nanomedicine market, with both quantitative and qualitative data, to help readers understand how the Cancer Nanomedicine market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the Cancer Nanomedicine market and forecasts the market size by Type (Inorganic Nanoparticles, Protein Nanoparticles and Polymer Nanoparticles), by Application (Breast Cancer, Pancreatic Cancer, Brain Cancer and Lung Cancer), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Inorganic Nanoparticles
Protein Nanoparticles
Polymer Nanoparticles
Lipid Organic Nanoparticles
Segmentation by application
Breast Cancer
Pancreatic Cancer
Brain Cancer
Lung Cancer
Other
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Alnylam Pharmaceuticals, Inc
Amgen Inc
Arrowhead Pharmaceuticals, Inc
AstraZeneca
Cadila Pharmaceuticals
CELGENE CORPORATION
Celsion Corporation
Genzyme
Merck & Co., Inc
Nippon Kayaku Co.,Ltd
Nanobiotix
Pfizer Inc
F. Hoffmann-La Roche Ltd
Takeda Pharmaceutical Company Limited
General Electric
Johnson & Johnson Services, Inc
Teva Pharmaceutical Industries Ltd
Gilead Sciences, Inc
Novartis AG
Chapter Introduction
Chapter 1: Scope of Cancer Nanomedicine, Research Methodology, etc.
Chapter 2: Executive Summary, global Cancer Nanomedicine market size (sales and revenue) and CAGR, Cancer Nanomedicine market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Cancer Nanomedicine sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Cancer Nanomedicine sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Cancer Nanomedicine market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Alnylam Pharmaceuticals, Inc, Amgen Inc, Arrowhead Pharmaceuticals, Inc, AstraZeneca, Cadila Pharmaceuticals, CELGENE CORPORATION, Celsion Corporation, Genzyme and Merck & Co., Inc, etc.
Chapter 14: Research Findings and Conclusion
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Cancer Nanomedicine Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Cancer Nanomedicine by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Cancer Nanomedicine by Country/Region, 2017, 2022 & 2028
2.2 Cancer Nanomedicine Segment by Type
2.2.1 Inorganic Nanoparticles
2.2.2 Protein Nanoparticles
2.2.3 Polymer Nanoparticles
2.2.4 Lipid Organic Nanoparticles
2.3 Cancer Nanomedicine Sales by Type
2.3.1 Global Cancer Nanomedicine Sales Market Share by Type (2017-2022)
2.3.2 Global Cancer Nanomedicine Revenue and Market Share by Type (2017-2022)
2.3.3 Global Cancer Nanomedicine Sale Price by Type (2017-2022)
2.4 Cancer Nanomedicine Segment by Application
2.4.1 Breast Cancer
2.4.2 Pancreatic Cancer
2.4.3 Brain Cancer
2.4.4 Lung Cancer
2.4.5 Other
2.5 Cancer Nanomedicine Sales by Application
2.5.1 Global Cancer Nanomedicine Sale Market Share by Application (2017-2022)
2.5.2 Global Cancer Nanomedicine Revenue and Market Share by Application (2017-2022)
2.5.3 Global Cancer Nanomedicine Sale Price by Application (2017-2022)
3 Global Cancer Nanomedicine by Company
3.1 Global Cancer Nanomedicine Breakdown Data by Company
3.1.1 Global Cancer Nanomedicine Annual Sales by Company (2020-2022)
3.1.2 Global Cancer Nanomedicine Sales Market Share by Company (2020-2022)
3.2 Global Cancer Nanomedicine Annual Revenue by Company (2020-2022)
3.2.1 Global Cancer Nanomedicine Revenue by Company (2020-2022)
3.2.2 Global Cancer Nanomedicine Revenue Market Share by Company (2020-2022)
3.3 Global Cancer Nanomedicine Sale Price by Company
3.4 Key Manufacturers Cancer Nanomedicine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Cancer Nanomedicine Product Location Distribution
3.4.2 Players Cancer Nanomedicine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Cancer Nanomedicine by Geographic Region
4.1 World Historic Cancer Nanomedicine Market Size by Geographic Region (2017-2022)
4.1.1 Global Cancer Nanomedicine Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Cancer Nanomedicine Annual Revenue by Geographic Region
4.2 World Historic Cancer Nanomedicine Market Size by Country/Region (2017-2022)
4.2.1 Global Cancer Nanomedicine Annual Sales by Country/Region (2017-2022)
4.2.2 Global Cancer Nanomedicine Annual Revenue by Country/Region
4.3 Americas Cancer Nanomedicine Sales Growth
4.4 APAC Cancer Nanomedicine Sales Growth
4.5 Europe Cancer Nanomedicine Sales Growth
4.6 Middle East & Africa Cancer Nanomedicine Sales Growth
5 Americas
5.1 Americas Cancer Nanomedicine Sales by Country
5.1.1 Americas Cancer Nanomedicine Sales by Country (2017-2022)
5.1.2 Americas Cancer Nanomedicine Revenue by Country (2017-2022)
5.2 Americas Cancer Nanomedicine Sales by Type
5.3 Americas Cancer Nanomedicine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cancer Nanomedicine Sales by Region
6.1.1 APAC Cancer Nanomedicine Sales by Region (2017-2022)
6.1.2 APAC Cancer Nanomedicine Revenue by Region (2017-2022)
6.2 APAC Cancer Nanomedicine Sales by Type
6.3 APAC Cancer Nanomedicine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Cancer Nanomedicine by Country
7.1.1 Europe Cancer Nanomedicine Sales by Country (2017-2022)
7.1.2 Europe Cancer Nanomedicine Revenue by Country (2017-2022)
7.2 Europe Cancer Nanomedicine Sales by Type
7.3 Europe Cancer Nanomedicine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Cancer Nanomedicine by Country
8.1.1 Middle East & Africa Cancer Nanomedicine Sales by Country (2017-2022)
8.1.2 Middle East & Africa Cancer Nanomedicine Revenue by Country (2017-2022)
8.2 Middle East & Africa Cancer Nanomedicine Sales by Type
8.3 Middle East & Africa Cancer Nanomedicine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Cancer Nanomedicine
10.3 Manufacturing Process Analysis of Cancer Nanomedicine
10.4 Industry Chain Structure of Cancer Nanomedicine
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Cancer Nanomedicine Distributors
11.3 Cancer Nanomedicine Customer
12 World Forecast Review for Cancer Nanomedicine by Geographic Region
12.1 Global Cancer Nanomedicine Market Size Forecast by Region
12.1.1 Global Cancer Nanomedicine Forecast by Region (2023-2028)
12.1.2 Global Cancer Nanomedicine Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Cancer Nanomedicine Forecast by Type
12.7 Global Cancer Nanomedicine Forecast by Application
13 Key Players Analysis
13.1 Alnylam Pharmaceuticals, Inc
13.1.1 Alnylam Pharmaceuticals, Inc Company Information
13.1.2 Alnylam Pharmaceuticals, Inc Cancer Nanomedicine Product Offered
13.1.3 Alnylam Pharmaceuticals, Inc Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Alnylam Pharmaceuticals, Inc Main Business Overview
13.1.5 Alnylam Pharmaceuticals, Inc Latest Developments
13.2 Amgen Inc
13.2.1 Amgen Inc Company Information
13.2.2 Amgen Inc Cancer Nanomedicine Product Offered
13.2.3 Amgen Inc Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Amgen Inc Main Business Overview
13.2.5 Amgen Inc Latest Developments
13.3 Arrowhead Pharmaceuticals, Inc
13.3.1 Arrowhead Pharmaceuticals, Inc Company Information
13.3.2 Arrowhead Pharmaceuticals, Inc Cancer Nanomedicine Product Offered
13.3.3 Arrowhead Pharmaceuticals, Inc Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Arrowhead Pharmaceuticals, Inc Main Business Overview
13.3.5 Arrowhead Pharmaceuticals, Inc Latest Developments
13.4 AstraZeneca
13.4.1 AstraZeneca Company Information
13.4.2 AstraZeneca Cancer Nanomedicine Product Offered
13.4.3 AstraZeneca Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 AstraZeneca Main Business Overview
13.4.5 AstraZeneca Latest Developments
13.5 Cadila Pharmaceuticals
13.5.1 Cadila Pharmaceuticals Company Information
13.5.2 Cadila Pharmaceuticals Cancer Nanomedicine Product Offered
13.5.3 Cadila Pharmaceuticals Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Cadila Pharmaceuticals Main Business Overview
13.5.5 Cadila Pharmaceuticals Latest Developments
13.6 CELGENE CORPORATION
13.6.1 CELGENE CORPORATION Company Information
13.6.2 CELGENE CORPORATION Cancer Nanomedicine Product Offered
13.6.3 CELGENE CORPORATION Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 CELGENE CORPORATION Main Business Overview
13.6.5 CELGENE CORPORATION Latest Developments
13.7 Celsion Corporation
13.7.1 Celsion Corporation Company Information
13.7.2 Celsion Corporation Cancer Nanomedicine Product Offered
13.7.3 Celsion Corporation Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Celsion Corporation Main Business Overview
13.7.5 Celsion Corporation Latest Developments
13.8 Genzyme
13.8.1 Genzyme Company Information
13.8.2 Genzyme Cancer Nanomedicine Product Offered
13.8.3 Genzyme Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Genzyme Main Business Overview
13.8.5 Genzyme Latest Developments
13.9 Merck & Co., Inc
13.9.1 Merck & Co., Inc Company Information
13.9.2 Merck & Co., Inc Cancer Nanomedicine Product Offered
13.9.3 Merck & Co., Inc Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Merck & Co., Inc Main Business Overview
13.9.5 Merck & Co., Inc Latest Developments
13.10 Nippon Kayaku Co.,Ltd
13.10.1 Nippon Kayaku Co.,Ltd Company Information
13.10.2 Nippon Kayaku Co.,Ltd Cancer Nanomedicine Product Offered
13.10.3 Nippon Kayaku Co.,Ltd Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Nippon Kayaku Co.,Ltd Main Business Overview
13.10.5 Nippon Kayaku Co.,Ltd Latest Developments
13.11 Nanobiotix
13.11.1 Nanobiotix Company Information
13.11.2 Nanobiotix Cancer Nanomedicine Product Offered
13.11.3 Nanobiotix Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Nanobiotix Main Business Overview
13.11.5 Nanobiotix Latest Developments
13.12 Pfizer Inc
13.12.1 Pfizer Inc Company Information
13.12.2 Pfizer Inc Cancer Nanomedicine Product Offered
13.12.3 Pfizer Inc Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Pfizer Inc Main Business Overview
13.12.5 Pfizer Inc Latest Developments
13.13 F. Hoffmann-La Roche Ltd
13.13.1 F. Hoffmann-La Roche Ltd Company Information
13.13.2 F. Hoffmann-La Roche Ltd Cancer Nanomedicine Product Offered
13.13.3 F. Hoffmann-La Roche Ltd Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 F. Hoffmann-La Roche Ltd Main Business Overview
13.13.5 F. Hoffmann-La Roche Ltd Latest Developments
13.14 Takeda Pharmaceutical Company Limited
13.14.1 Takeda Pharmaceutical Company Limited Company Information
13.14.2 Takeda Pharmaceutical Company Limited Cancer Nanomedicine Product Offered
13.14.3 Takeda Pharmaceutical Company Limited Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 Takeda Pharmaceutical Company Limited Main Business Overview
13.14.5 Takeda Pharmaceutical Company Limited Latest Developments
13.15 General Electric
13.15.1 General Electric Company Information
13.15.2 General Electric Cancer Nanomedicine Product Offered
13.15.3 General Electric Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.15.4 General Electric Main Business Overview
13.15.5 General Electric Latest Developments
13.16 Johnson & Johnson Services, Inc
13.16.1 Johnson & Johnson Services, Inc Company Information
13.16.2 Johnson & Johnson Services, Inc Cancer Nanomedicine Product Offered
13.16.3 Johnson & Johnson Services, Inc Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.16.4 Johnson & Johnson Services, Inc Main Business Overview
13.16.5 Johnson & Johnson Services, Inc Latest Developments
13.17 Teva Pharmaceutical Industries Ltd
13.17.1 Teva Pharmaceutical Industries Ltd Company Information
13.17.2 Teva Pharmaceutical Industries Ltd Cancer Nanomedicine Product Offered
13.17.3 Teva Pharmaceutical Industries Ltd Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.17.4 Teva Pharmaceutical Industries Ltd Main Business Overview
13.17.5 Teva Pharmaceutical Industries Ltd Latest Developments
13.18 Gilead Sciences, Inc
13.18.1 Gilead Sciences, Inc Company Information
13.18.2 Gilead Sciences, Inc Cancer Nanomedicine Product Offered
13.18.3 Gilead Sciences, Inc Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.18.4 Gilead Sciences, Inc Main Business Overview
13.18.5 Gilead Sciences, Inc Latest Developments
13.19 Novartis AG
13.19.1 Novartis AG Company Information
13.19.2 Novartis AG Cancer Nanomedicine Product Offered
13.19.3 Novartis AG Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.19.4 Novartis AG Main Business Overview
13.19.5 Novartis AG Latest Developments
14 Research Findings and Conclusion
Tables and Figures
List of Tables
Table 1. Cancer Nanomedicine Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Cancer Nanomedicine Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Inorganic Nanoparticles
Table 4. Major Players of Protein Nanoparticles
Table 5. Major Players of Polymer Nanoparticles
Table 6. Major Players of Lipid Organic Nanoparticles
Table 7. Global Cancer Nanomedicine Sales by Type (2017-2022) & (K Units)
Table 8. Global Cancer Nanomedicine Sales Market Share by Type (2017-2022)
Table 9. Global Cancer Nanomedicine Revenue by Type (2017-2022) & ($ million)
Table 10. Global Cancer Nanomedicine Revenue Market Share by Type (2017-2022)
Table 11. Global Cancer Nanomedicine Sale Price by Type (2017-2022) & (US$/Unit)
Table 12. Global Cancer Nanomedicine Sales by Application (2017-2022) & (K Units)
Table 13. Global Cancer Nanomedicine Sales Market Share by Application (2017-2022)
Table 14. Global Cancer Nanomedicine Revenue by Application (2017-2022)
Table 15. Global Cancer Nanomedicine Revenue Market Share by Application (2017-2022)
Table 16. Global Cancer Nanomedicine Sale Price by Application (2017-2022) & (US$/Unit)
Table 17. Global Cancer Nanomedicine Sales by Company (2020-2022) & (K Units)
Table 18. Global Cancer Nanomedicine Sales Market Share by Company (2020-2022)
Table 19. Global Cancer Nanomedicine Revenue by Company (2020-2022) ($ Millions)
Table 20. Global Cancer Nanomedicine Revenue Market Share by Company (2020-2022)
Table 21. Global Cancer Nanomedicine Sale Price by Company (2020-2022) & (US$/Unit)
Table 22. Key Manufacturers Cancer Nanomedicine Producing Area Distribution and Sales Area
Table 23. Players Cancer Nanomedicine Products Offered
Table 24. Cancer Nanomedicine Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Cancer Nanomedicine Sales by Geographic Region (2017-2022) & (K Units)
Table 28. Global Cancer Nanomedicine Sales Market Share Geographic Region (2017-2022)
Table 29. Global Cancer Nanomedicine Revenue by Geographic Region (2017-2022) & ($ millions)
Table 30. Global Cancer Nanomedicine Revenue Market Share by Geographic Region (2017-2022)
Table 31. Global Cancer Nanomedicine Sales by Country/Region (2017-2022) & (K Units)
Table 32. Global Cancer Nanomedicine Sales Market Share by Country/Region (2017-2022)
Table 33. Global Cancer Nanomedicine Revenue by Country/Region (2017-2022) & ($ millions)
Table 34. Global Cancer Nanomedicine Revenue Market Share by Country/Region (2017-2022)
Table 35. Americas Cancer Nanomedicine Sales by Country (2017-2022) & (K Units)
Table 36. Americas Cancer Nanomedicine Sales Market Share by Country (2017-2022)
Table 37. Americas Cancer Nanomedicine Revenue by Country (2017-2022) & ($ Millions)
Table 38. Americas Cancer Nanomedicine Revenue Market Share by Country (2017-2022)
Table 39. Americas Cancer Nanomedicine Sales by Type (2017-2022) & (K Units)
Table 40. Americas Cancer Nanomedicine Sales Market Share by Type (2017-2022)
Table 41. Americas Cancer Nanomedicine Sales by Application (2017-2022) & (K Units)
Table 42. Americas Cancer Nanomedicine Sales Market Share by Application (2017-2022)
Table 43. APAC Cancer Nanomedicine Sales by Region (2017-2022) & (K Units)
Table 44. APAC Cancer Nanomedicine Sales Market Share by Region (2017-2022)
Table 45. APAC Cancer Nanomedicine Revenue by Region (2017-2022) & ($ Millions)
Table 46. APAC Cancer Nanomedicine Revenue Market Share by Region (2017-2022)
Table 47. APAC Cancer Nanomedicine Sales by Type (2017-2022) & (K Units)
Table 48. APAC Cancer Nanomedicine Sales Market Share by Type (2017-2022)
Table 49. APAC Cancer Nanomedicine Sales by Application (2017-2022) & (K Units)
Table 50. APAC Cancer Nanomedicine Sales Market Share by Application (2017-2022)
Table 51. Europe Cancer Nanomedicine Sales by Country (2017-2022) & (K Units)
Table 52. Europe Cancer Nanomedicine Sales Market Share by Country (2017-2022)
Table 53. Europe Cancer Nanomedicine Revenue by Country (2017-2022) & ($ Millions)
Table 54. Europe Cancer Nanomedicine Revenue Market Share by Country (2017-2022)
Table 55. Europe Cancer Nanomedicine Sales by Type (2017-2022) & (K Units)
Table 56. Europe Cancer Nanomedicine Sales Market Share by Type (2017-2022)
Table 57. Europe Cancer Nanomedicine Sales by Application (2017-2022) & (K Units)
Table 58. Europe Cancer Nanomedicine Sales Market Share by Application (2017-2022)
Table 59. Middle East & Africa Cancer Nanomedicine Sales by Country (2017-2022) & (K Units)
Table 60. Middle East & Africa Cancer Nanomedicine Sales Market Share by Country (2017-2022)
Table 61. Middle East & Africa Cancer Nanomedicine Revenue by Country (2017-2022) & ($ Millions)
Table 62. Middle East & Africa Cancer Nanomedicine Revenue Market Share by Country (2017-2022)
Table 63. Middle East & Africa Cancer Nanomedicine Sales by Type (2017-2022) & (K Units)
Table 64. Middle East & Africa Cancer Nanomedicine Sales Market Share by Type (2017-2022)
Table 65. Middle East & Africa Cancer Nanomedicine Sales by Application (2017-2022) & (K Units)
Table 66. Middle East & Africa Cancer Nanomedicine Sales Market Share by Application (2017-2022)
Table 67. Key Market Drivers & Growth Opportunities of Cancer Nanomedicine
Table 68. Key Market Challenges & Risks of Cancer Nanomedicine
Table 69. Key Industry Trends of Cancer Nanomedicine
Table 70. Cancer Nanomedicine Raw Material
Table 71. Key Suppliers of Raw Materials
Table 72. Cancer Nanomedicine Distributors List
Table 73. Cancer Nanomedicine Customer List
Table 74. Global Cancer Nanomedicine Sales Forecast by Region (2023-2028) & (K Units)
Table 75. Global Cancer Nanomedicine Sales Market Forecast by Region
Table 76. Global Cancer Nanomedicine Revenue Forecast by Region (2023-2028) & ($ millions)
Table 77. Global Cancer Nanomedicine Revenue Market Share Forecast by Region (2023-2028)
Table 78. Americas Cancer Nanomedicine Sales Forecast by Country (2023-2028) & (K Units)
Table 79. Americas Cancer Nanomedicine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 80. APAC Cancer Nanomedicine Sales Forecast by Region (2023-2028) & (K Units)
Table 81. APAC Cancer Nanomedicine Revenue Forecast by Region (2023-2028) & ($ millions)
Table 82. Europe Cancer Nanomedicine Sales Forecast by Country (2023-2028) & (K Units)
Table 83. Europe Cancer Nanomedicine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Middle East & Africa Cancer Nanomedicine Sales Forecast by Country (2023-2028) & (K Units)
Table 85. Middle East & Africa Cancer Nanomedicine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 86. Global Cancer Nanomedicine Sales Forecast by Type (2023-2028) & (K Units)
Table 87. Global Cancer Nanomedicine Sales Market Share Forecast by Type (2023-2028)
Table 88. Global Cancer Nanomedicine Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 89. Global Cancer Nanomedicine Revenue Market Share Forecast by Type (2023-2028)
Table 90. Global Cancer Nanomedicine Sales Forecast by Application (2023-2028) & (K Units)
Table 91. Global Cancer Nanomedicine Sales Market Share Forecast by Application (2023-2028)
Table 92. Global Cancer Nanomedicine Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 93. Global Cancer Nanomedicine Revenue Market Share Forecast by Application (2023-2028)
Table 94. Alnylam Pharmaceuticals, Inc Basic Information, Cancer Nanomedicine Manufacturing Base, Sales Area and Its Competitors
Table 95. Alnylam Pharmaceuticals, Inc Cancer Nanomedicine Product Offered
Table 96. Alnylam Pharmaceuticals, Inc Cancer Nanomedicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 97. Alnylam Pharmaceuticals, Inc Main Business
Table 98. Alnylam Pharmaceuticals, Inc Latest Developments
Table 99. Amgen Inc Basic Information, Cancer Nanomedicine Manufacturing Base, Sales Area and Its Competitors
Table 100. Amgen Inc Cancer Nanomedicine Product Offered
Table 101. Amgen Inc Cancer Nanomedicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 102. Amgen Inc Main Business
Table 103. Amgen Inc Latest Developments
Table 104. Arrowhead Pharmaceuticals, Inc Basic Information, Cancer Nanomedicine Manufacturing Base, Sales Area and Its Competitors
Table 105. Arrowhead Pharmaceuticals, Inc Cancer Nanomedicine Product Offered
Table 106. Arrowhead Pharmaceuticals, Inc Cancer Nanomedicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 107. Arrowhead Pharmaceuticals, Inc Main Business
Table 108. Arrowhead Pharmaceuticals, Inc Latest Developments
Table 109. AstraZeneca Basic Information, Cancer Nanomedicine Manufacturing Base, Sales Area and Its Competitors
Table 110. AstraZeneca Cancer Nanomedicine Product Offered
Table 111. AstraZeneca Cancer Nanomedicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 112. AstraZeneca Main Business
Table 113. AstraZeneca Latest Developments
Table 114. Cadila Pharmaceuticals Basic Information, Cancer Nanomedicine Manufacturing Base, Sales Area and Its Competitors
Table 115. Cadila Pharmaceuticals Cancer Nanomedicine Product Offered
Table 116. Cadila Pharmaceuticals Cancer Nanomedicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 117. Cadila Pharmaceuticals Main Business
Table 118. Cadila Pharmaceuticals Latest Developments
Table 119. CELGENE CORPORATION Basic Information, Cancer Nanomedicine Manufacturing Base, Sales Area and Its Competitors
Table 120. CELGENE CORPORATION Cancer Nanomedicine Product Offered
Table 121. CELGENE CORPORATION Cancer Nanomedicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 122. CELGENE CORPORATION Main Business
Table 123. CELGENE CORPORATION Latest Developments
Table 124. Celsion Corporation Basic Information, Cancer Nanomedicine Manufacturing Base, Sales Area and Its Competitors
Table 125. Celsion Corporation Cancer Nanomedicine Product Offered
Table 126. Celsion Corporation Cancer Nanomedicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 127. Celsion Corporation Main Business
Table 128. Celsion Corporation Latest Developments
Table 129. Genzyme Basic Information, Cancer Nanomedicine Manufacturing Base, Sales Area and Its Competitors
Table 130. Genzyme Cancer Nanomedicine Product Offered
Table 131. Genzyme Cancer Nanomedicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 132. Genzyme Main Business
Table 133. Genzyme Latest Developments
Table 134. Merck & Co., Inc Basic Information, Cancer Nanomedicine Manufacturing Base, Sales Area and Its Competitors
Table 135. Merck & Co., Inc Cancer Nanomedicine Product Offered
Table 136. Merck & Co., Inc Cancer Nanomedicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 137. Merck & Co., Inc Main Business
Table 138. Merck & Co., Inc Latest Developments
Table 139. Nippon Kayaku Co.,Ltd Basic Information, Cancer Nanomedicine Manufacturing Base, Sales Area and Its Competitors
Table 140. Nippon Kayaku Co.,Ltd Cancer Nanomedicine Product Offered
Table 141. Nippon Kayaku Co.,Ltd Cancer Nanomedicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 142. Nippon Kayaku Co.,Ltd Main Business
Table 143. Nippon Kayaku Co.,Ltd Latest Developments
Table 144. Nanobiotix Basic Information, Cancer Nanomedicine Manufacturing Base, Sales Area and Its Competitors
Table 145. Nanobiotix Cancer Nanomedicine Product Offered
Table 146. Nanobiotix Cancer Nanomedicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 147. Nanobiotix Main Business
Table 148. Nanobiotix Latest Developments
Table 149. Pfizer Inc Basic Information, Cancer Nanomedicine Manufacturing Base, Sales Area and Its Competitors
Table 150. Pfizer Inc Cancer Nanomedicine Product Offered
Table 151. Pfizer Inc Cancer Nanomedicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 152. Pfizer Inc Main Business
Table 153. Pfizer Inc Latest Developments
Table 154. F. Hoffmann-La Roche Ltd Basic Information, Cancer Nanomedicine Manufacturing Base, Sales Area and Its Competitors
Table 155. F. Hoffmann-La Roche Ltd Cancer Nanomedicine Product Offered
Table 156. F. Hoffmann-La Roche Ltd Cancer Nanomedicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 157. F. Hoffmann-La Roche Ltd Main Business
Table 158. F. Hoffmann-La Roche Ltd Latest Developments
Table 159. Takeda Pharmaceutical Company Limited Basic Information, Cancer Nanomedicine Manufacturing Base, Sales Area and Its Competitors
Table 160. Takeda Pharmaceutical Company Limited Cancer Nanomedicine Product Offered
Table 161. Takeda Pharmaceutical Company Limited Cancer Nanomedicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 162. Takeda Pharmaceutical Company Limited Main Business
Table 163. Takeda Pharmaceutical Company Limited Latest Developments
Table 164. General Electric Basic Information, Cancer Nanomedicine Manufacturing Base, Sales Area and Its Competitors
Table 165. General Electric Cancer Nanomedicine Product Offered
Table 166. General Electric Cancer Nanomedicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 167. General Electric Main Business
Table 168. General Electric Latest Developments
Table 169. Johnson & Johnson Services, Inc Basic Information, Cancer Nanomedicine Manufacturing Base, Sales Area and Its Competitors
Table 170. Johnson & Johnson Services, Inc Cancer Nanomedicine Product Offered
Table 171. Johnson & Johnson Services, Inc Cancer Nanomedicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 172. Johnson & Johnson Services, Inc Main Business
Table 173. Johnson & Johnson Services, Inc Latest Developments
Table 174. Teva Pharmaceutical Industries Ltd Basic Information, Cancer Nanomedicine Manufacturing Base, Sales Area and Its Competitors
Table 175. Teva Pharmaceutical Industries Ltd Cancer Nanomedicine Product Offered
Table 176. Teva Pharmaceutical Industries Ltd Cancer Nanomedicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 177. Teva Pharmaceutical Industries Ltd Main Business
Table 178. Teva Pharmaceutical Industries Ltd Latest Developments
Table 179. Gilead Sciences, Inc Basic Information, Cancer Nanomedicine Manufacturing Base, Sales Area and Its Competitors
Table 180. Gilead Sciences, Inc Cancer Nanomedicine Product Offered
Table 181. Gilead Sciences, Inc Cancer Nanomedicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 182. Gilead Sciences, Inc Main Business
Table 183. Gilead Sciences, Inc Latest Developments
Table 184. Novartis AG Basic Information, Cancer Nanomedicine Manufacturing Base, Sales Area and Its Competitors
Table 185. Novartis AG Cancer Nanomedicine Product Offered
Table 186. Novartis AG Cancer Nanomedicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 187. Novartis AG Main Business
Table 188. Novartis AG Latest Developments
List of Figures
Figure 1. Picture of Cancer Nanomedicine
Figure 2. Cancer Nanomedicine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Cancer Nanomedicine Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Cancer Nanomedicine Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Cancer Nanomedicine Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Inorganic Nanoparticles
Figure 10. Product Picture of Protein Nanoparticles
Figure 11. Product Picture of Polymer Nanoparticles
Figure 12. Product Picture of Lipid Organic Nanoparticles
Figure 13. Global Cancer Nanomedicine Sales Market Share by Type in 2021
Figure 14. Global Cancer Nanomedicine Revenue Market Share by Type (2017-2022)
Figure 15. Cancer Nanomedicine Consumed in Breast Cancer
Figure 16. Global Cancer Nanomedicine Market: Breast Cancer (2017-2022) & (K Units)
Figure 17. Cancer Nanomedicine Consumed in Pancreatic Cancer
Figure 18. Global Cancer Nanomedicine Market: Pancreatic Cancer (2017-2022) & (K Units)
Figure 19. Cancer Nanomedicine Consumed in Brain Cancer
Figure 20. Global Cancer Nanomedicine Market: Brain Cancer (2017-2022) & (K Units)
Figure 21. Cancer Nanomedicine Consumed in Lung Cancer
Figure 22. Global Cancer Nanomedicine Market: Lung Cancer (2017-2022) & (K Units)
Figure 23. Cancer Nanomedicine Consumed in Other
Figure 24. Global Cancer Nanomedicine Market: Other (2017-2022) & (K Units)
Figure 25. Global Cancer Nanomedicine Sales Market Share by Application (2017-2022)
Figure 26. Global Cancer Nanomedicine Revenue Market Share by Application in 2021
Figure 27. Cancer Nanomedicine Revenue Market by Company in 2021 ($ Million)
Figure 28. Global Cancer Nanomedicine Revenue Market Share by Company in 2021
Figure 29. Global Cancer Nanomedicine Sales Market Share by Geographic Region (2017-2022)
Figure 30. Global Cancer Nanomedicine Revenue Market Share by Geographic Region in 2021
Figure 31. Global Cancer Nanomedicine Sales Market Share by Region (2017-2022)
Figure 32. Global Cancer Nanomedicine Revenue Market Share by Country/Region in 2021
Figure 33. Americas Cancer Nanomedicine Sales 2017-2022 (K Units)
Figure 34. Americas Cancer Nanomedicine Revenue 2017-2022 ($ Millions)
Figure 35. APAC Cancer Nanomedicine Sales 2017-2022 (K Units)
Figure 36. APAC Cancer Nanomedicine Revenue 2017-2022 ($ Millions)
Figure 37. Europe Cancer Nanomedicine Sales 2017-2022 (K Units)
Figure 38. Europe Cancer Nanomedicine Revenue 2017-2022 ($ Millions)
Figure 39. Middle East & Africa Cancer Nanomedicine Sales 2017-2022 (K Units)
Figure 40. Middle East & Africa Cancer Nanomedicine Revenue 2017-2022 ($ Millions)
Figure 41. Americas Cancer Nanomedicine Sales Market Share by Country in 2021
Figure 42. Americas Cancer Nanomedicine Revenue Market Share by Country in 2021
Figure 43. United States Cancer Nanomedicine Revenue Growth 2017-2022 ($ Millions)
Figure 44. Canada Cancer Nanomedicine Revenue Growth 2017-2022 ($ Millions)
Figure 45. Mexico Cancer Nanomedicine Revenue Growth 2017-2022 ($ Millions)
Figure 46. Brazil Cancer Nanomedicine Revenue Growth 2017-2022 ($ Millions)
Figure 47. APAC Cancer Nanomedicine Sales Market Share by Region in 2021
Figure 48. APAC Cancer Nanomedicine Revenue Market Share by Regions in 2021
Figure 49. China Cancer Nanomedicine Revenue Growth 2017-2022 ($ Millions)
Figure 50. Japan Cancer Nanomedicine Revenue Growth 2017-2022 ($ Millions)
Figure 51. South Korea Cancer Nanomedicine Revenue Growth 2017-2022 ($ Millions)
Figure 52. Southeast Asia Cancer Nanomedicine Revenue Growth 2017-2022 ($ Millions)
Figure 53. India Cancer Nanomedicine Revenue Growth 2017-2022 ($ Millions)
Figure 54. Australia Cancer Nanomedicine Revenue Growth 2017-2022 ($ Millions)
Figure 55. Europe Cancer Nanomedicine Sales Market Share by Country in 2021
Figure 56. Europe Cancer Nanomedicine Revenue Market Share by Country in 2021
Figure 57. Germany Cancer Nanomedicine Revenue Growth 2017-2022 ($ Millions)
Figure 58. France Cancer Nanomedicine Revenue Growth 2017-2022 ($ Millions)
Figure 59. UK Cancer Nanomedicine Revenue Growth 2017-2022 ($ Millions)
Figure 60. Italy Cancer Nanomedicine Revenue Growth 2017-2022 ($ Millions)
Figure 61. Russia Cancer Nanomedicine Revenue Growth 2017-2022 ($ Millions)
Figure 62. Middle East & Africa Cancer Nanomedicine Sales Market Share by Country in 2021
Figure 63. Middle East & Africa Cancer Nanomedicine Revenue Market Share by Country in 2021
Figure 64. Egypt Cancer Nanomedicine Revenue Growth 2017-2022 ($ Millions)
Figure 65. South Africa Cancer Nanomedicine Revenue Growth 2017-2022 ($ Millions)
Figure 66. Israel Cancer Nanomedicine Revenue Growth 2017-2022 ($ Millions)
Figure 67. Turkey Cancer Nanomedicine Revenue Growth 2017-2022 ($ Millions)
Figure 68. GCC Country Cancer Nanomedicine Revenue Growth 2017-2022 ($ Millions)
Figure 69. Manufacturing Cost Structure Analysis of Cancer Nanomedicine in 2021
Figure 70. Manufacturing Process Analysis of Cancer Nanomedicine
Figure 71. Industry Chain Structure of Cancer Nanomedicine
Figure 72. Channels of Distribution
Figure 73. Distributors Profiles
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets